« Back to Record
Citation APA

Kirschbrown, W. W., Kågedal, M., Wang, B., Lindbom, L., Knott, A., Mack, R., Monemi, S., Nijem, I., Girish, S., Freeman, C., Fumagalli, D., McConnell, R., Jerusalem, G., Twelves, C., Baselga, J., Von Minckwitz, G., Bines, J., & Garg, A. X. (2019). Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer chemotherapy and pharmacology, 83(6), 1147-1158. doi:10.1007/s00280-019-03826-1


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/290293

Kirschbrown, W. W., Kågedal, M., Wang, B., Lindbom, L., Knott, A., Mack, R., Monemi, S., Nijem, I., Girish, S., Freeman, C., Fumagalli, D., McConnell, R., Jerusalem, G., Twelves, C., Baselga, J., Von Minckwitz, G., Bines, J., & Garg, A. X. (2019). Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. Cancer chemotherapy and pharmacology, 83(6), 1147-1158. doi:10.1007/s00280-019-03826-1